An update on the cause and treatment of scleritis

Aleksandra Rachitskaya, Efrem D. Mandelcorn, Thomas A. Albini

Research output: Contribution to journalReview articlepeer-review

18 Scopus citations


Purpose of review: To review new clinically relevant data regarding the cause and treatment of scleritis that has been identified over the past 36 months. Recent findings: A recently described T-helper cell population, known as Th-17, has been implicated in scleritis. Large-scale, retrospective reviews of standard corticosteroid-sparing systemic therapies, published in the last few years, have demonstrated only moderate efficacy for any particular immunomodulatory agent, whereas new data have confirmed excellent efficacy and tolerability to subconjunctival corticosteroids. Summary: Improved understanding of the immunopathophysiology of scleritis offers hope for future molecule-specific drug design. Data continue to support the use of local steroids as a reasonable therapeutic option for nonnecrotizing, noninfectious anterior scleritis.

Original languageEnglish (US)
Pages (from-to)463-467
Number of pages5
JournalCurrent opinion in ophthalmology
Issue number6
StatePublished - Nov 1 2010


  • noninfectious anterior scleritis
  • ocular disease
  • scleritis

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'An update on the cause and treatment of scleritis'. Together they form a unique fingerprint.

Cite this